 BOSTON, Oct. 20, 2021 GLOBE NEWSWIRE -- Monte Rosa Therapeutics, Inc. NASDAQ: GLUE, a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on Wednesday, Oct. 27 at 11:45 a.m. ET. The presentation, titled, Molecular Glue Degraders: From Serendipity to Rational Design, will showcase the capabilities of Monte Rosas QuEENTM Quantitative and Engineered Elimination of Neosubstrates platform and its impact on expanding target space. 